Neuroblastoma Mistaken for Acute Leukemia Based on Bone Marrow Morphology
Ding Mei,Li Ying,Fang Xiao-sheng,Wang Jian-hong,Wang Xin
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20121967
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:To the editor: A 15-year-old girl presented to the Hematology Outpatient Department of the Provincial Hospital Affiliated to Shandong University (China) with anemia and thrombocytopenia. Clinical investigation revealed pale lips, a few petechiae in her upper and lower limbs. Specifically, the firm, immobile and painless breast masses were noted to be approximately 8 cm. The preliminary bone marrow morphology in the community hospital indicated that the percentage of blast-like cells was high to 90.5% and she was diagnosed as acute leukemia. Further leukemia immunophenotyping of single cell suspension showed the abnormal cells in bone marrow expressing CD56, CD81, partly expressing CD57, and rarely expressing CD117, CD34, HLA-DR, CD7, CD28, CD19, CD138, GlyA, cCD3, CD41a, cMPO, and cCD79a. After ultrasound-guided percutaneous aspiration biopsy of the right breast, pathology indicated neuroblastoma. And the computed tomography (CT) scan revealed an expansile soft tissue mass in her pelvic cavity, which was considered the primary tumor, and lymphatic metastasis to pelvic cavity and bilateral inguina. We ultimately diagnosed the patient as neuroblastoma (stage IV). Neuroblastoma is the most common extracranial solid tumor mostly occurring in children under 10 years. It is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts. The incidence of neuroblastoma is about 7% to 8% in childhood. However, in over 60% of cases, the disease has been metastatic at the time of diagnosis,1 these cases of neuroblastoma pose a diagnostic challenge due to its nonspecific significances and high metastasis, and delay in diagnosis often leads to potentially inappropriate clinical management and poor prognosis. The diagnosis of neuroblastoma was confirmed by the histopathology of surgery remove or fine-needle aspiration biospy, additionally, some serological biomarkers often play an important role in the determination of tumor stages and prognosis, SF >150 mg/L, LDH >1500 U/L, or NSE >100 μg/L, sometimes mean a poorer prognosis. Genetic and molecular changes in the tumor, such as chromosome 1p deletion, gain of chromosome 17q, DNA ploidy, high expression of neurotrophin receptors (TrkA and TrkB) and especially amplification of MYCN oncogene, portend a poorer prognosis.2,3 Contemporary treatment of neuroblastoma is tailored according to the biological behavior of the disease, which is best delineated by the patient age, disease staging according to the international neuroblastoma staging system (INSS) and molecular changes. Earlystaged patients are often cured with tranditional treatment, and the event-free survival rate of five years is about 70%-90%. The majority of children with metastatic diseases (stage 3 and 4) wound succumb even after intense treatment with chemotherapy, surgery and high-dose therapy followed by hematopoietic stem cell transplantation. However, conventional chemotherapy has been ineffective after relapse in these patients, and they can not tolerate additional intensive treatment because they had been intensively treated previously; therefore, a new modality of treatment is warranted for these patients. In recent years, several groups of investigators have examined the feasibility and effectiveness of reduced-intensity allogenic stem cell transplantation (RI alloSCT) for the treatment of relapsed/progressed neuroblastoma,4 which lead to engraftment of donor lymphoid and hematopoietic stem cells without the extra-hematopoietic toxicities of standard myeloablative conditioning, and still conserve the graftversus-leukemia (GVL) or GVT effect. The RI alloSCT is particularly suitable for patients at high-risk of treatment-related mortality, especially previous HDCT/autoSCT recipients, and a therapeutic benefit will emerge. Moreover, a few clinical trials of tandem HDCT/autoSCT, high-dose 131I-meta-iodobenzylguanidine (MIBG) treatment incorporated into HDCT/autoSCT,5 and anti-GD2 treatment after HDCT/autoSCT, are currently underway to improve the survival of high-risk NB patients.